Healthcare
Live Price
Offline$31.43
+0.74% today
1Y Change
+160.78%
Window
Jun 23, 2025 → May 29, 2026
Coverage: 236 bars · Jun 23, 2025 → May 29, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Roivant Sciences Ltd. (ROIV) is a Healthcare stock with a market cap of $19.92B and listed on NASDAQ. The stock last traded around $31.43 and up 160.8% across the available one-year price window (Jun 23, 2025 → May 29, 2026). Baseline metrics include revenue growth of -11.2%, EPS growth of -104.3%, a dividend yield of 0.0%. What stands out right now is revenue -11.2%, EPS -104.3%, free cash flow -10.1% with operating margin -9130.5% and ROIC -23.9%. Valuation already assumes a fairly strong business story at price/sales 1496.5. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines ROIV price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
ROIV
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
ROIV Max Drawdown
-11.21%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for ROIV and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$23.8M
-57.0% YoY
FY Net Income
-$809.2M
+4.3% YoY
Free Cash Flow
-$557.9M
+19.7% YoY
Revenue Growth
-11.2%
EPS Growth
-104.3%
Gross Margin
91.2%
Net Margin
-6079.9%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 29M | 33M | 61M | 55M | 24M |
| Gross Profit | 28M | 31M | 48M | 46M | 22M |
| Operating Income | -1.0B | 4.5B | -1.2B | -1.4B | -1.1B |
| EBITDA | -1.1B | -803M | -1.2B | -911M | -721M |
| Net Income | -172M | 4.3B | -1.0B | -845M | -809M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 2.7B | 6.5B | 1.7B | 2.1B | 2.1B |
| Total Assets | 5.4B | 7.2B | 2.4B | 2.6B | 2.7B |
| Total Liabilities | 250M | 774M | 782M | 524M | 528M |
| Shareholder Equity | 4.7B | 6.0B | 1.2B | 1.7B | 1.9B |
| Total Debt | 100M | 500M | 481M | 284M | 245M |
| Net Debt | -2.6B | -6.0B | -1.2B | -1.8B | -1.9B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
552M
+18.5% YoY
Capital Expenditures
6M
+66.7% YoY
Free Cash Flow
558M
+19.7% YoY
Key ratios
Gross Margin
91.2%
Operating Margin
-9130.5%
Net Margin
-6079.9%
ROE
-18.3%
Debt / Equity
0.05x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.